Figure 2.

CD11a‐EPCR+ KLS cells outcompete CD11a+ counterparts in competitive transplants. (A): Representation of competitive transplant system. Group 1 recipients (outlined symbols in B–E) received CFP+ CD11a– EPCR+ KLS and Tomato+ CD11a+ KLS, and Group 2 (borderless symbols in B–E) received Tomato+ CD11a– EPCR+ KLS and CFP+ CD11a+ KLS. 3,000 CD11a– EPCR+ KLS and 10,000 CD11a+ KLS sorted cells (physiological ratios) along with 100,000 helper WBM (from Wt B6 mice) were co‐transplanted into each lethally irradiated B6 recipient. (B, C): Time‐course analysis of donor chimerism in blood. Total (B) and granulocyte (C) blood chimerism from CD11a– EPCR+ KLS (“CD11a– EPCR+”) and CD11a+ KLS (“CD11a+”) sources in primary recipients at weeks (W) 4, 8, and 12 post‐transplant. (D): Donor chimerism of HSCs in the BM of primary recipients 13 weeks post‐transplant. HSCs are defined as Ter119– CD27+ Sca‐1+ Kit+ CD11a– EPCR+. (E): Blood granulocyte chimerism in secondary recipients 6 weeks post‐secondary transplant. Secondary transplants were done using 1 × 10⁶ WBM harvested from primary recipients 13 weeks after the primary transplantation. **, p ≤ .01; ***, p ≤ .001 (Student's unpaired t test). Abbreviations: BM, bone marrow, HSCs, hematopoietic stem cells.